Drugs / Bevacizumabl
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07044921 Background | Sep 2024 → Jul 2026 overdue | colorectal cancer | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevacizumabl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07044921 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT07044921 ↗ |